C Liedtke

1.7k total citations · 1 hit paper
47 papers, 965 citations indexed

About

C Liedtke is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C Liedtke has authored 47 papers receiving a total of 965 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Cancer Research, 26 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C Liedtke's work include Breast Cancer Treatment Studies (36 papers), HER2/EGFR in Cancer Research (14 papers) and Advanced Breast Cancer Therapies (13 papers). C Liedtke is often cited by papers focused on Breast Cancer Treatment Studies (36 papers), HER2/EGFR in Cancer Research (14 papers) and Advanced Breast Cancer Therapies (13 papers). C Liedtke collaborates with scholars based in Germany, United States and Switzerland. C Liedtke's co-authors include Lajos Pusztai, Ulrike Nitz, Nadia Harbeck, Oleg Gluz, Nina Gottschalk, Ludwig Kiesel, W. Fraser Symmans, Shu‐Wan Kau, Gabriel N. Hortobágyi and Ana M. González-Angulo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

C Liedtke

42 papers receiving 946 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple-negative breast cancer—current status and future directions

2009 513 citations Oleg Gluz, C Liedtke et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C Liedtke Germany	10	604	543	311	206	136	47	965
Charlene Kay United Kingdom	16	443 0.7×	366 0.7×	433 1.4×	193 0.9×	158 1.2×	31	954
Margarita Viladot Spain	6	464 0.8×	449 0.8×	379 1.2×	185 0.9×	83 0.6×	12	905
Kimberly B. Koenig United States	12	510 0.8×	475 0.9×	245 0.8×	203 1.0×	160 1.2×	15	855
Marc Díez Spain	6	510 0.8×	431 0.8×	459 1.5×	285 1.4×	85 0.6×	15	1.1k
Frédéric Commo France	19	468 0.8×	461 0.8×	545 1.8×	368 1.8×	96 0.7×	32	1.1k
Ángel Guerrero‐Zotano Spain	12	454 0.8×	445 0.8×	735 2.4×	188 0.9×	94 0.7×	29	1.1k
R.K. Gregory United Kingdom	13	564 0.9×	410 0.8×	208 0.7×	116 0.6×	213 1.6×	19	874
Laxmi Silwal‐Pandit Norway	13	420 0.7×	367 0.7×	404 1.3×	175 0.8×	77 0.6×	21	800
Anne‐Lise Børresen‐Dale Norway	15	446 0.7×	527 1.0×	822 2.6×	123 0.6×	210 1.5×	20	1.2k
Kinisha Gala United States	7	532 0.9×	409 0.8×	524 1.7×	412 2.0×	366 2.7×	10	1.1k

Countries citing papers authored by C Liedtke

Since Specialization

Citations

This map shows the geographic impact of C Liedtke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Liedtke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Liedtke more than expected).

Fields of papers citing papers by C Liedtke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Liedtke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Liedtke. The network helps show where C Liedtke may publish in the future.

Co-authorship network of co-authors of C Liedtke

This figure shows the co-authorship network connecting the top 25 collaborators of C Liedtke. A scholar is included among the top collaborators of C Liedtke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Liedtke. C Liedtke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gluz, Oleg, Ulrike Nitz, C Liedtke, et al.. (2018). Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology. 29. viii703–viii703. 4 indexed citations

Liedtke, C, Hans‐Christian Kolberg, Laura Kerschke, et al.. (2018). Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). Clinical & Experimental Metastasis. 35(8). 777–783. 9 indexed citations

Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results. Annals of Oncology. 28. v606–v606. 1 indexed citations

Gluz, Oleg, Michael Clemens, Stefan Kraemer, et al.. (2016). Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. European Journal of Cancer. 5 indexed citations

Gluz, Oleg, C Liedtke, Jens Huober, et al.. (2016). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Annals of Oncology. 27(6). 1035–1040. 10 indexed citations

Liedtke, C, et al.. (2016). Supplementary Material for: AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016. Figshare. 3 indexed citations

Juhasz‐Böss, Ingolf, Christoph Gerlinger, Achim Rody, et al.. (2016). Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. Geburtshilfe und Frauenheilkunde. 76(10). 1 indexed citations

Fasching, Peter A., et al.. (2016). Targeted Intraoperative Radiation Therapy Tumor Bed Boost During Breast-Conserving Surgery After Neoadjuvant Chemotherapy in TNBC and HER2 Positive Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 96(2). E6–E7. 1 indexed citations

Würstlein, Rachel & C Liedtke. (2013). Kongressbericht. Combating Breast Cancer 2013: Chance auf Heilung. Geburtshilfe und Frauenheilkunde. 73(12). 1178–1180. 1 indexed citations

10.

Liedtke, C & Ludwig Kiesel. (2012). Chemotherapy-Induced Amenorrhea – An Update. Geburtshilfe und Frauenheilkunde. 72(9). 809–818. 8 indexed citations

11.

Loibl, Sibylle, G von Minckwitz, Serafín Morales, et al.. (2012). Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study.. Cancer Research. 72(24_Supplement). S1–7. 14 indexed citations

12.

Gluz, Oleg, Matthias Christgen, C Liedtke, et al.. (2012). Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial. Cancer Research. 72(24_Supplement). P2–10. 3 indexed citations

13.

Gluz, Oleg, Ramona Erber, Hans Kreipe, et al.. (2011). P1-06-03: Predictive Value of HER2, Topoisomerase-II (Topo-II) and Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy of Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer – Results from the EC-Doc Trial.. Cancer Research. 71(24_Supplement). P1–6. 1 indexed citations

14.

Degenhardt, Tom, Oleg Gluz, Ronald Kates, et al.. (2011). Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.. Journal of Clinical Oncology. 29(15_suppl). 10594–10594. 3 indexed citations

15.

Gluz, Oleg, C Liedtke, Susanne Markmann, et al.. (2010). WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1.. Journal of Clinical Oncology. 28(15_suppl). TPS106–TPS106. 2 indexed citations

16.

Liedtke, C, Kristine Broglio, Stacey Moulder, et al.. (2009). Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Annals of Oncology. 20(12). 1953–1958. 228 indexed citations

17.

Gluz, Oleg, C Liedtke, Nina Gottschalk, et al.. (2009). Triple-negative breast cancer—current status and future directions. Annals of Oncology. 20(12). 1913–1927. 513 indexed citations breakdown →

18.

Liedtke, C, et al.. (2009). Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant Chemotherapy.. Cancer Research. 69(24_Supplement). 4047–4047. 2 indexed citations

19.

Mathieu, Marie, Chafika Mazouni, C Liedtke, et al.. (2008). Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Annals of Oncology. 19(8). 1402–1406. 13 indexed citations

20.

Moulder, SL, Linda Hsu, Shu‐Wan Kau, et al.. (2008). Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1001–1001. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact